GLP1R and type 2 diabetes mellitus: The introduction of GLP-1-R agonists is also substantiated by The Diabetes, Cardiorenal, and Metabolism task force, which considers such drugs to be effective in primary and secondary stroke prevention in subjects with T2DM [69].